Medicines for hepatitis C remain in the high-cost protection after TLV's reconsideration

TLV

18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis C drugs that are included in the high-cost protection. 

In parallel with the review, the regions and pharmaceutical companies have negotiated new side agreements which mean that the costs of hepatitis C drugs are reduced. 

This has resulted in the drugs continuing to be included in the high-cost protection for all patients.

Read TLV News [Swedish]

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Market access , Sweden